TGFB1 and neoplasm: This ECM-based immune evasion signature outperforms traditional biomarkers such as tumor mutation burden, cytolytic activity, TGF-β expression, CAF abundance, and T-cell-inflamed signatures in predicting immune checkpoint blockade response.